Ryu Kariyawasam-Chavez, Content Associate

Apnimed has submitted an NDA for AD109 for obstructive sleep apnea following positive phase 3 results from the SynAIRgy and LunAIRo trials.

A real-world study presented at ASCO 2026 found that early intravenous immunoglobulin administration within 4 weeks of starting talquetamab was associated with significantly lower infection rates and reduced 1-year mortality in patients with relapsed or refractory multiple myeloma.

Updated results from a phase 1 study showed that KLN-1010 produced reduced MRD-negative responses in all treated patients with RRMM.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss how medication stigma and bias can impact patient recovery.

Final results from the CEPHEUS trial showed that daratumumab plus VRd produced deeper, more durable responses and prolonged survival.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss why patients struggle to access mental health and addiction treatment medications.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss how stigma from health care providers or frontline staff impacts patient willingness to seek or continue treatment.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss common myths and misconceptions surrounding antidepressants, antipsychotics, and medications for addiction treatment in congregate care settings.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Jacci Bainbridge, PharmD, FCCP, Professor Vice Chair for Research and Scholarship, Neurology Pharmacy, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking long-term MS therapy, de-escalation, biomarkers and the future of care for MS.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Patricia K. Coyle, MD, a Director at the MS Center at Stony Brook Medicine, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking escalation strategies in relapsing MS.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Donald Langan, PharmD, MD, a Multiple Sclerosis and Clinical Neuroimmunology Fellow at Columbia University, presenting on the evolution of GLP-1 receptor agonists, discussed the future of GLP-1 therapies and the expansion of the pharmacist's role.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what the pharmacist's role in MS supplement safety.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what works and what doesn't in MS supplements.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic, presenting on management of High-risk multiple sclerosis patients, discussed what the pharmacist's role is in managing high-risk MS patients.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic presenting on management of High-risk multiple sclerosis patients, discussed safety, treatment, and emerging strategies.

Pharmacy Times speaks with Sarah Sparks, MHA, MBA, Director of Clinical Data Quality at Ontada, through strengthening oncology real-world data quality through clinically relevant edit checks.

Pharmacy Times speaks with Helen Latimer, MPH, to discuss the advancement of HRR genetic testing equity in metastatic prostate cancer.

Pharmacy Times speaks with Jeff Goad, PhD, MPH, a professor of pharmacy practice at Chapman University, on the role pharmacists play during outbreaks or rising measles cases.

Pharmacy Times speaks with Jeff Goad, PhD, MPH, about the biggest misconceptions surrounding measles and the MMR vaccine, as well as the serious symptoms pharmacists believe patients should never ignore.

Pharmacy Times interviews Sarah Spark, MHA, MBA, Director of Clinical Data Quality at Ontada, on how clinically relevant edit checks are improving the accuracy and reliability of real-world oncology data to better support clinical decision-making, research, and patient outcomes.

FACT-accredited centers vs nonaccredited centers may influence CAR T-cell therapy outcomes.

The findings emphasize the growing role of precision oncology and integrated EHR infrastructure in expanding access to targeted therapies.

Pharmacy Times interviews Helen Latimer, MPH, about new real-world data examining racial disparities and evolving trends in HRR genetic testing among patients with metastatic prostate cancer and the implications for equitable access to precision oncology care.

Six-year follow-up data from the SEQUOIA trial showed that zanubrutinib provided durable PFS and strong long-term outcomes in treatment-naïve CLL/SLL.

An overview of how earlier use of CAR T-cell therapy is reshaping multiple myeloma treatment and what pharmacists should know about toxicity management, supportive care, and evolving clinical practice.

Data from a phase 1/2 trial revealed that CRISPR–Cas9–edited donor stem cell transplants lacking CD33 enabled rapid engraftment and allowed posttransplant gemtuzumab ozogamicin maintenance in high-risk patients with AML/MDS without prolonged hematologic toxicity.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the safety profile of Levorphanol compared with methadone, including potential reductions in risks such as accumulation, QT prolongation, and drug interactions, as well as its implications for clinical workflows and the pharmacist’s role in supporting safe opioid rotation, monitoring, and patient counseling.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and examines how levorphanol compares to methadone in pharmacology and clinical efficacy, as well as the key evidence supporting its use and the practical barriers clinicians face when transitioning between the two agents in complex pain management.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the clinical scenarios and patient populations that prompted the consideration of levorphanol as a methadone-sparing option in complex pain management.

Ketamine, an NMDA receptor antagonist, is increasingly being used in low-dose infusions as a multimodal, opioid-sparing strategy for patients with refractory acute and chronic pain.